AndhraNews.net
Home » Business News » 2013 » November » November 12, 2013

Affimed Therapeutics Appoints Dr. Jens-Peter Marschner as Chief Medical Officer


November 12, 2013 - London

Affimed Therapeutics AG /Affimed Therapeutics Appoints Dr. Jens-Peter Marschner as Chief Medical Officer. Ad hoc announcement according to § 15 WpHG. Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Heidelberg, Germany, November 12, 2013: Affimed Therapeutics AG, the TandAb antibody company, announced today the appointment of Dr. Jens-Peter Marschner as Chief Medical Officer, effective October 1st, 2013.

Dr. Marschner recently joined Affimed from Merck KGaA. He has 18 years of professional experience in clinical development with a focus on biological compounds. Working in several pharmaceutical companies, he has been responsible for conducting clinical trials in all phases of development. Dr. Marschner led the clinical development team of cetuximab (Erbitux), a monoclonal antibody to treat colorectal cancer, which was successfully launched in 2004. During his career he has also been responsible for the early and late stage development of cancer immune therapies. As VP Global Medical Affairs at Merck KGaA Dr. Marschner gained comprehensive experience in market-related medical and scientific affairs, primarily in the field of oncology.

Dr. Adi Hoess, CEO of Affimed Therapeutics, commented: "I am delighted to welcome Jens-Peter as a key member of the Executive Management Board. His expert knowledge and experience in oncology drug development and management adds significantly to our company and our future. Jens-Peter's expertise will ensure that Affimed continues to build on its leadership in the development of bispecific immunotherapies."  

"Bi-specific antibodies will play a major role in the future treatment of cancer. Affimed's TandAb® technology has the potential to provide major benefit to patients affected by hematologic malignancies, which our lead compounds target," said Dr. Jens-Peter Marschner, CMO of Affimed Therapeutics. "The opportunity to help patients by developing these promising antibodies is a strong motivator for my work and I am very excited to join the team."

Dr. Marschner initially trained and worked as a medical doctor. After finishing the clinical work at a general hospital (internal medicine) he worked at the University Hospital Frankfurt/Main where he became a board certified Clinical Pharmacologist. He started his pharmaceutical career in 1995 at Boehringer Mannheim, which is now part of Roche. After a shorter tenure at Bayer he joined Merck KGaA in 1999. Along with his responsibility for the development of several biological compounds he managed different global teams in Clinical Development and Medical Affairs.

For further information please contact:

Affimed Therapeutics AG
Dr. Adi Hoess (CEO)
Tel.: + 49 6221 65307 0
Fax: + 49 6221 65307 77
a.hoess@affimed.com
MC Services AG
Anne Hennecke
Tel.: +49 89 210 228 18
Fax: +49 89 210 228 88
anne.hennecke@mc-services.eu

About TandAbs and Affimed's immunotherapeutic product candidates
TandAbs®, which were invented and developed by Affimed scientists, are tetravalent bispecific antibody formats that have two binding sites for each antigen. They bind to target molecules on the surface of tumor cells and specifically activate immune effector cells such as cytotoxic T cells or natural killer (NK) cells in the presence of tumor cells. This simultaneous binding to both cells leads to an effective lysis of the tumor cells. TandAbs® possess the same avidity and affinity for each target as an IgG. Combined with their bispecificity, this format represents a potent further development of therapeutic monoclonal antibodies and, potentially, a superior alternative to first generation antibody formats/scaffolds.

AFM11 and AFM13 are Affimed's lead product candidates. The TandAb® AFM11 is specifically designed to treat CD19-positive malignancies. It targets CD19 on malignant B cells and engages CD3 on T cells. AFM11 recently has been filed with regulatory agencies for the initiation of phase 1 clinical trials. The TandAb® AFM13 is specifically designed to treat CD30-positive malignancies. It targets CD30 on malignant cells and CD16A on NK cells. AFM13 has shown an attractive safety profile and demonstrated a clinical effect in a Phase 1 study in relapsing/refractory Hodgkin lymphoma patients.

About Affimed Therapeutics AG
Affimed Therapeutics AG is a therapeutic antibody company developing unique antibody therapeutics as novel treatments for life threatening diseases with high unmet medical needs. The company has generated a growing pipeline of drug candidates based on its proprietary TandAb® antibody platform. Affimed's product candidates are developed for the treatment of CD19-positive (AFM11) and CD30-positive tumors (AFM13). Further novel product candidates are in development to treat solid tumors and autoimmune diseases. Affimed's proprietary and highly productive TandAb® technology enables the company to generate unique tetravalent, bispecific, fully human antibody formats that promise increased therapeutic potential and superior profiles compared to monoclonal antibodies. The private company Affimed, which employs 30 people in Heidelberg, is a spin-off from the German Cancer Research Centre (DKFZ), Heidelberg.

Press release (PDF)



This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Affimed Therapeutics AG via Thomson Reuters ONE

HUG#1742263

GlobeNewswire

Comment on this story

Share